» Articles » PMID: 1471873

The Oxidant Stress Hypothesis in Parkinson's Disease: Evidence Supporting It

Overview
Journal Ann Neurol
Specialty Neurology
Date 1992 Dec 1
PMID 1471873
Citations 175
Authors
Affiliations
Soon will be listed here.
Abstract

Oxidant stress, due to the formation of hydrogen peroxide and oxygen-derived free radicals, can cause cell damage due to chain reactions of membrane lipid peroxidation. Because the substantia nigra is rich in dopamine, which can undergo both enzymatic oxidation via monoamine oxidase and nonenzymatic autoxidation, hydrogen peroxide and oxyradicals (superoxide anion radical and hydroxyl radical) are generated in this midbrain nucleus. Although proof that oxidant stress actually causes the loss of monoaminergic neurons in patients with Parkinson's disease is lacking, there is a considerable body of evidence from studies in both animals and humans that support the concept. (1) Neurotoxins that selectively destroy the dopaminergic neurons in the nigra, such as 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), appear to act via oxidant stress. (2) The substantia nigra of patients with Parkinson's disease reveals evidence of oxidant stress by the findings of increased lipid peroxidation and decreased reduced glutathione. (3) Total iron is increased and ferritin is reduced in the substantia nigra pars compacta in patients with Parkinson's disease. This combination suggests that this transition metal is in a low molecular weight form, capable of catalyzing nonenzymatic oxidative reactions, especially the conversion of hydrogen peroxide to hydroxyl radical, which is the most reactive of the oxygen radicals. (4) Neuromelanin, a product of dopamine autoxidation, can serve as a reservoir for iron, promoting the generation of oxyradicals. (5) Antioxidant defense mechanisms appear to be reduced in the parkinsonian substantia nigra with the findings of decreased activities of glutathione peroxidase and catalase.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential.

Capasso L, De Masi L, Sirignano C, Maresca V, Basile A, Nebbioso A Molecules. 2025; 30(3).

PMID: 39942757 PMC: 11821029. DOI: 10.3390/molecules30030654.


Mass Spectrometry Analysis of Neurotransmitter Shifting during Neurogenesis and Neurodegeneration of PC12 Cells.

Jao Y, Chao Y, Chan J, Hsu Y Int J Mol Sci. 2024; 25(19).

PMID: 39408728 PMC: 11477332. DOI: 10.3390/ijms251910399.


Neurodegenerative diseases and catechins: (-)-epigallocatechin-3-gallate is a modulator of chronic neuroinflammation and oxidative stress.

Li S, Wang Z, Liu G, Chen M Front Nutr. 2024; 11:1425839.

PMID: 39149548 PMC: 11326534. DOI: 10.3389/fnut.2024.1425839.


Myricetin mitigates motor disturbance and decreases neuronal ferroptosis in a rat model of Parkinson's disease.

Gu S, Xie Z, Gu M, Wang C, Xu L, Gao C Sci Rep. 2024; 14(1):15107.

PMID: 38956066 PMC: 11219851. DOI: 10.1038/s41598-024-62910-6.


Nuclear aggregates of NONO/SFPQ and A-to-I-edited RNA in Parkinson's disease and dementia with Lewy bodies.

Belur N, Bustos B, Lubbe S, Mazzulli J Neuron. 2024; 112(15):2558-2580.e13.

PMID: 38761794 PMC: 11309915. DOI: 10.1016/j.neuron.2024.05.003.